https://www.selleckchem.com/pr....oducts/filanesib.htm
Hemodialysis is the most common mode of therapy worldwide for chronic kidney disease (CKD) and is used as a life-sustaining therapy for most of the patients. Studies proved that dialysis affects the Quality of life (QOL) of patients. Health-related quality of life has been increasingly recognized as an important medical outcome in patients with CKD. Kidney disease quality of life short form (KDQOL-SF™) is developed by RAND to assess the QOL in CKD patients. This study was conducted to translate and validate the questionnaire KDQOL-SF™
Like
Comment
Share
